Cargando…
Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022056/ https://www.ncbi.nlm.nih.gov/pubmed/35449061 http://dx.doi.org/10.1186/s13063-022-06266-0 |
| _version_ | 1784689994428841984 |
|---|---|
| author | Halford, Sarah Wan, Susan Dragoni, Ilaria Silvester, Julie Nazarov, Bobojon Anthony, Daniel Anthony, Suzie Ladds, Emma Norrie, John Dhaliwal, Kevin |
| author_facet | Halford, Sarah Wan, Susan Dragoni, Ilaria Silvester, Julie Nazarov, Bobojon Anthony, Daniel Anthony, Suzie Ladds, Emma Norrie, John Dhaliwal, Kevin |
| author_sort | Halford, Sarah |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9022056 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90220562022-04-21 Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion Halford, Sarah Wan, Susan Dragoni, Ilaria Silvester, Julie Nazarov, Bobojon Anthony, Daniel Anthony, Suzie Ladds, Emma Norrie, John Dhaliwal, Kevin Trials Correction BioMed Central 2022-04-21 /pmc/articles/PMC9022056/ /pubmed/35449061 http://dx.doi.org/10.1186/s13063-022-06266-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Halford, Sarah Wan, Susan Dragoni, Ilaria Silvester, Julie Nazarov, Bobojon Anthony, Daniel Anthony, Suzie Ladds, Emma Norrie, John Dhaliwal, Kevin Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_full | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_fullStr | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_full_unstemmed | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_short | Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion |
| title_sort | correction to: spike-1: a randomised phase ii/iii trial in a community setting, assessing use of camostat in reducing the clinical progression of covid-19 by blocking sars-cov-2 spike protein-initiated membrane fusion |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022056/ https://www.ncbi.nlm.nih.gov/pubmed/35449061 http://dx.doi.org/10.1186/s13063-022-06266-0 |
| work_keys_str_mv | AT halfordsarah correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT wansusan correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT dragoniilaria correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT silvesterjulie correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT nazarovbobojon correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT anthonydaniel correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT anthonysuzie correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT laddsemma correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT norriejohn correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT dhaliwalkevin correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion AT correctiontospike1arandomisedphaseiiiiitrialinacommunitysettingassessinguseofcamostatinreducingtheclinicalprogressionofcovid19byblockingsarscov2spikeproteininitiatedmembranefusion |